Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Thomas Flaig

Concepts (370)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
29
2021
191
8.010
Why?
Prostatic Neoplasms
35
2020
957
6.350
Why?
Prostatic Neoplasms, Castration-Resistant
18
2021
40
4.540
Why?
Kidney Neoplasms
22
2021
330
4.390
Why?
Antineoplastic Agents
28
2021
2035
3.870
Why?
Antineoplastic Combined Chemotherapy Protocols
25
2021
1390
3.830
Why?
Carcinoma, Renal Cell
17
2021
175
3.820
Why?
Androgen Antagonists
14
2020
83
3.050
Why?
Pyrroles
7
2017
203
1.950
Why?
Indoles
7
2017
348
1.780
Why?
Carcinoma, Transitional Cell
6
2020
45
1.770
Why?
Medical Oncology
5
2020
207
1.710
Why?
Abiraterone Acetate
9
2021
15
1.610
Why?
Neoplasm Metastasis
24
2021
610
1.560
Why?
Urothelium
3
2016
31
1.560
Why?
Prednisone
14
2021
247
1.370
Why?
Taxoids
7
2017
94
1.360
Why?
Adenocarcinoma
7
2020
808
1.340
Why?
Phenylurea Compounds
6
2016
90
1.330
Why?
Mitoxantrone
5
2018
18
1.290
Why?
Antineoplastic Agents, Hormonal
8
2017
146
1.280
Why?
Niacinamide
5
2016
72
1.240
Why?
Orchiectomy
4
2014
56
1.190
Why?
Urologic Neoplasms
4
2021
24
1.180
Why?
Prostate-Specific Antigen
10
2021
162
1.160
Why?
Male
81
2021
60817
1.000
Why?
Phenylthiohydantoin
6
2021
39
0.960
Why?
Carcinoma
2
2016
207
0.940
Why?
Humans
110
2021
114571
0.920
Why?
Aged
51
2021
20218
0.910
Why?
Neoplasm Staging
11
2021
1215
0.900
Why?
ErbB Receptors
6
2018
553
0.870
Why?
Nitriles
10
2021
162
0.830
Why?
Immunotherapy
4
2018
459
0.810
Why?
Protein Kinase Inhibitors
6
2014
853
0.810
Why?
Treatment Outcome
27
2021
9190
0.760
Why?
Aged, 80 and over
25
2021
6818
0.760
Why?
Radiosurgery
4
2015
299
0.740
Why?
Bone Neoplasms
3
2015
198
0.720
Why?
Disease-Free Survival
12
2017
685
0.710
Why?
Testicular Neoplasms
2
2021
84
0.700
Why?
Viscera
2
2014
19
0.690
Why?
Sulfonamides
2
2012
455
0.690
Why?
Antibodies, Monoclonal, Humanized
3
2021
654
0.690
Why?
Hematologic Diseases
2
2016
57
0.680
Why?
Prostatectomy
5
2018
111
0.650
Why?
Antineoplastic Agents, Immunological
2
2020
155
0.650
Why?
Erythrocytes, Abnormal
1
2016
16
0.650
Why?
Neoadjuvant Therapy
5
2021
283
0.640
Why?
Benzamides
7
2021
186
0.640
Why?
Liver Neoplasms
3
2017
457
0.640
Why?
Middle Aged
41
2021
28854
0.630
Why?
Receptors, Androgen
2
2021
119
0.600
Why?
Genomics
2
2018
514
0.600
Why?
Practice Guidelines as Topic
3
2019
1541
0.590
Why?
Urinary Bladder
2
2018
150
0.590
Why?
Pancreatitis
1
2016
106
0.590
Why?
Silymarin
4
2013
211
0.540
Why?
Leydig Cell Tumor
1
2014
8
0.540
Why?
Epithelial-Mesenchymal Transition
2
2016
171
0.500
Why?
Multicenter Studies as Topic
2
2021
222
0.490
Why?
Proto-Oncogene Proteins p21(ras)
1
2013
238
0.470
Why?
Carcinoma, Basal Cell
1
2013
63
0.470
Why?
Hypothyroidism
1
2012
71
0.470
Why?
Sarcoma
1
2013
132
0.460
Why?
Diethylstilbestrol
1
2011
13
0.450
Why?
Therapies, Investigational
1
2011
16
0.450
Why?
Gene Expression Profiling
1
2018
1561
0.450
Why?
Angiomyolipoma
1
2011
21
0.450
Why?
Leukemia, Myeloid, Acute
2
2008
484
0.440
Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
105
0.440
Why?
Chemotherapy, Adjuvant
6
2018
327
0.430
Why?
Neoplastic Cells, Circulating
1
2011
63
0.430
Why?
Prognosis
10
2020
3546
0.430
Why?
Androstenes
4
2015
12
0.420
Why?
Lung Neoplasms
5
2017
2191
0.410
Why?
Disease Progression
10
2021
2486
0.410
Why?
Receptors, Fibroblast Growth Factor
1
2010
65
0.400
Why?
Neoplasms, Multiple Primary
1
2010
51
0.390
Why?
Cystectomy
3
2018
27
0.390
Why?
Molecular Targeted Therapy
1
2013
380
0.390
Why?
Tumor Suppressor Protein p53
1
2013
460
0.390
Why?
Recombinant Fusion Proteins
1
2012
694
0.380
Why?
Kaplan-Meier Estimate
8
2016
899
0.380
Why?
Neoplasm Proteins
1
2013
436
0.380
Why?
Lymphatic Diseases
1
2009
17
0.380
Why?
Neuroblastoma
1
2010
127
0.380
Why?
Adult
25
2021
32077
0.380
Why?
Vascular Endothelial Growth Factors
1
2009
85
0.380
Why?
Cystitis
1
2009
23
0.380
Why?
Antineoplastic Agents, Phytogenic
2
2010
194
0.370
Why?
Vascular Endothelial Growth Factor A
2
2019
518
0.370
Why?
Pneumatosis Cystoides Intestinalis
1
2008
12
0.360
Why?
Pyrazoles
1
2012
399
0.360
Why?
Precision Medicine
1
2011
294
0.360
Why?
Androstadienes
3
2013
102
0.360
Why?
Intestinal Perforation
1
2008
49
0.350
Why?
Double-Blind Method
12
2021
1681
0.350
Why?
Survival Rate
9
2021
1859
0.350
Why?
Carcinoma, Squamous Cell
1
2013
555
0.350
Why?
Testosterone
3
2021
321
0.340
Why?
Pyrimidines
1
2011
408
0.340
Why?
Pancreatic Neoplasms
1
2014
704
0.340
Why?
Clinical Trials as Topic
5
2018
1004
0.340
Why?
Female
26
2021
63070
0.330
Why?
Neoplasm Invasiveness
3
2019
450
0.330
Why?
BCG Vaccine
2
2018
31
0.320
Why?
Androgen Receptor Antagonists
3
2021
31
0.320
Why?
Nanotubes
2
2018
43
0.310
Why?
Survival Analysis
6
2021
1410
0.310
Why?
Combined Modality Therapy
9
2020
1217
0.310
Why?
Quinazolines
4
2019
245
0.310
Why?
United States
9
2018
12551
0.310
Why?
Neoplasm Grading
6
2018
242
0.310
Why?
Carboplatin
1
2006
140
0.300
Why?
Skin Neoplasms
1
2013
755
0.300
Why?
Gold
2
2018
101
0.300
Why?
Cell Line, Tumor
7
2018
2887
0.290
Why?
Lymphatic Metastasis
2
2018
313
0.290
Why?
Cisplatin
5
2021
276
0.290
Why?
Gonadotropin-Releasing Hormone
2
2020
199
0.290
Why?
Randomized Controlled Trials as Topic
3
2021
1159
0.280
Why?
Drug Resistance, Neoplasm
3
2018
681
0.280
Why?
Retrospective Studies
8
2020
11642
0.270
Why?
Radiotherapy, Adjuvant
2
2018
194
0.270
Why?
Dexamethasone
1
2006
310
0.270
Why?
Drug Synergism
3
2011
360
0.270
Why?
Societies, Medical
2
2018
764
0.260
Why?
Androstenols
3
2015
4
0.260
Why?
Tosyl Compounds
4
2018
21
0.250
Why?
Steroid 17-alpha-Hydroxylase
2
2014
4
0.250
Why?
Drug Administration Schedule
4
2021
808
0.250
Why?
Anilides
4
2018
78
0.240
Why?
Vitamin D
1
2006
347
0.240
Why?
Dose-Response Relationship, Drug
5
2013
2187
0.240
Why?
Tumor Microenvironment
2
2018
393
0.240
Why?
Gene Expression Regulation, Neoplastic
2
2021
1199
0.240
Why?
Biomarkers, Tumor
3
2021
1051
0.230
Why?
Retroperitoneal Space
1
2021
14
0.230
Why?
Thiohydantoins
1
2021
2
0.230
Why?
Tissue Extracts
2
2012
27
0.220
Why?
Indazoles
2
2012
69
0.220
Why?
Administration, Intravesical
2
2018
12
0.220
Why?
Kallikreins
2
2019
38
0.220
Why?
Neoplasms, Germ Cell and Embryonal
1
2021
41
0.220
Why?
Retreatment
1
2021
70
0.220
Why?
Databases, Factual
2
2016
1161
0.210
Why?
Neoplasm Recurrence, Local
3
2018
805
0.210
Why?
Bone Marrow Transplantation
1
2002
268
0.210
Why?
Quality of Life
3
2021
2230
0.200
Why?
Genetic Heterogeneity
1
2020
57
0.200
Why?
Tomography, X-Ray Computed
4
2014
2379
0.200
Why?
Phosphatidylcholines
2
2013
135
0.200
Why?
Yttrium
1
2018
7
0.190
Why?
Antibodies, Monoclonal
2
2020
1294
0.190
Why?
Euterpe
1
2018
7
0.190
Why?
Fluorides
1
2018
51
0.190
Why?
Angiogenesis Inhibitors
2
2021
221
0.180
Why?
In Situ Hybridization, Fluorescence
2
2011
340
0.180
Why?
Time Factors
5
2020
7029
0.180
Why?
Cell Adhesion Molecules
1
2020
184
0.180
Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
6
0.180
Why?
Organ Sparing Treatments
1
2018
31
0.180
Why?
Lymph Node Excision
2
2021
143
0.180
Why?
Piperidines
2
2010
182
0.180
Why?
Patient Reported Outcome Measures
1
2020
216
0.180
Why?
Congresses as Topic
2
2012
202
0.170
Why?
Central Nervous System
1
2020
249
0.170
Why?
Neoplasm, Residual
2
2021
91
0.170
Why?
Tumor Escape
1
2018
40
0.170
Why?
Antioxidants
2
2013
557
0.170
Why?
History, 21st Century
2
2015
200
0.170
Why?
Cancer Vaccines
1
2019
150
0.170
Why?
Odds Ratio
1
2021
1059
0.170
Why?
Genome
1
2020
259
0.170
Why?
Proton Therapy
1
2017
10
0.170
Why?
Microscopy, Fluorescence
3
2018
435
0.160
Why?
Goserelin
3
2018
12
0.160
Why?
Erythrocyte Indices
1
2016
26
0.160
Why?
Apoptosis
1
2007
2607
0.160
Why?
Aftercare
1
2018
171
0.160
Why?
Plant Extracts
1
2018
173
0.160
Why?
Biopsy
3
2018
1048
0.160
Why?
Blotting, Western
2
2010
1296
0.160
Why?
Watchful Waiting
1
2016
53
0.160
Why?
Dyslipidemias
1
2018
157
0.150
Why?
Fatal Outcome
2
2008
315
0.150
Why?
Adverse Drug Reaction Reporting Systems
1
2016
70
0.150
Why?
Practice Patterns, Physicians'
2
2016
1241
0.150
Why?
Oligopeptides
1
2018
271
0.150
Why?
High-Throughput Nucleotide Sequencing
1
2018
413
0.150
Why?
United States Food and Drug Administration
1
2016
185
0.150
Why?
SEER Program
3
2014
206
0.140
Why?
Prostate
2
2021
151
0.140
Why?
Soft Tissue Neoplasms
1
2015
91
0.140
Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
4
0.140
Why?
Nanoparticles
1
2018
333
0.140
Why?
Disease Management
1
2019
605
0.140
Why?
Ablation Techniques
1
2014
28
0.140
Why?
Radiation Tolerance
1
2015
101
0.140
Why?
Mitotic Index
1
2014
28
0.130
Why?
Insurance, Health
1
2016
263
0.130
Why?
Patient Selection
1
2018
707
0.130
Why?
Neoplasms, Hormone-Dependent
1
2014
39
0.130
Why?
Neoplasms, Complex and Mixed
1
2013
8
0.130
Why?
Carcinoma, Medullary
1
2013
14
0.130
Why?
Hyperthermia, Induced
1
2014
72
0.130
Why?
Breeding
1
2013
60
0.130
Why?
beta-Galactosidase
1
2013
81
0.130
Why?
Milk Thistle
1
2013
41
0.130
Why?
Sirolimus
2
2014
187
0.130
Why?
Interleukin-2
1
2014
402
0.120
Why?
Glucocorticoids
1
2018
550
0.120
Why?
Geriatrics
1
2014
78
0.120
Why?
Hyperplasia
1
2013
161
0.120
Why?
Urogenital Neoplasms
1
2012
6
0.120
Why?
Staining and Labeling
1
2013
167
0.120
Why?
Magnetic Resonance Imaging
3
2021
3145
0.120
Why?
Receptor, ErbB-2
1
2016
328
0.120
Why?
Tumor Stem Cell Assay
1
2012
39
0.120
Why?
Keratins
1
2013
183
0.120
Why?
Brain Neoplasms
1
2021
982
0.120
Why?
Adenoviridae
1
2013
184
0.120
Why?
Organ Specificity
1
2013
296
0.120
Why?
Nephrectomy
2
2013
150
0.120
Why?
Integrases
1
2013
115
0.120
Why?
Reproducibility of Results
2
2013
2926
0.120
Why?
Fluorescent Antibody Technique
1
2013
429
0.120
Why?
Celecoxib
1
2012
40
0.120
Why?
Bone Diseases
1
2012
52
0.120
Why?
Thyroid Hormones
1
2012
63
0.120
Why?
Thyroid Gland
1
2012
91
0.120
Why?
Population Surveillance
1
2015
440
0.120
Why?
Cell Proliferation
2
2012
2368
0.120
Why?
Quinolines
1
2013
140
0.110
Why?
RNA, Untranslated
1
2013
123
0.110
Why?
Cross-Over Studies
3
2021
488
0.110
Why?
Carcinoma, Hepatocellular
1
2013
193
0.110
Why?
Reoperation
1
2014
546
0.110
Why?
PubMed
1
2010
11
0.110
Why?
Denosumab
1
2010
7
0.110
Why?
Imidazoles
1
2012
264
0.110
Why?
RANK Ligand
1
2010
30
0.110
Why?
Benzenesulfonates
1
2010
23
0.110
Why?
Erlotinib Hydrochloride
1
2010
68
0.100
Why?
Vimentin
1
2010
62
0.100
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
37
0.100
Why?
Cell Separation
1
2011
307
0.100
Why?
Xenograft Model Antitumor Assays
1
2012
779
0.100
Why?
Animals
5
2016
34687
0.100
Why?
Mesoderm
1
2010
143
0.100
Why?
Nephrolithiasis
1
2009
9
0.100
Why?
Hypertension
1
2018
1186
0.100
Why?
Carcinoma, Papillary
1
2009
77
0.100
Why?
Metaplasia
1
2009
57
0.090
Why?
Cadherins
1
2010
187
0.090
Why?
Cardiovascular Diseases
2
2018
1683
0.090
Why?
Gynecomastia
1
2008
6
0.090
Why?
Tumor Cells, Cultured
1
2011
1002
0.090
Why?
Chromatography, Liquid
1
2010
340
0.090
Why?
Insulin-Like Growth Factor I
1
2010
275
0.090
Why?
Age Factors
1
2016
3280
0.090
Why?
Tandem Mass Spectrometry
1
2010
385
0.090
Why?
Liver Failure, Acute
1
2008
56
0.090
Why?
Southwestern United States
1
2008
96
0.090
Why?
Risk Factors
5
2018
9078
0.090
Why?
Risk
1
2011
943
0.090
Why?
Mediastinal Diseases
1
2007
10
0.090
Why?
Drug Therapy, Combination
1
2011
1004
0.090
Why?
Genotype
1
2013
1848
0.090
Why?
Hormone Replacement Therapy
1
2008
81
0.090
Why?
Carcinoid Tumor
1
2007
21
0.090
Why?
Mice, Transgenic
1
2013
2101
0.090
Why?
Proportional Hazards Models
3
2016
1188
0.080
Why?
Neoplasms, Second Primary
1
2008
73
0.080
Why?
Glucuronides
1
2006
21
0.080
Why?
Spectrophotometry, Ultraviolet
1
2006
90
0.080
Why?
Medical History Taking
1
2007
127
0.080
Why?
Pyridines
1
2010
498
0.080
Why?
Liver Function Tests
1
2006
116
0.080
Why?
Mice
2
2013
15429
0.080
Why?
Excipients
1
2006
89
0.080
Why?
Sarcoidosis
1
2007
118
0.080
Why?
Antibiotics, Antineoplastic
1
2006
117
0.080
Why?
Syndrome
1
2007
342
0.080
Why?
Chemistry, Pharmaceutical
1
2006
162
0.080
Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
177
0.080
Why?
Everolimus
2
2017
56
0.080
Why?
Pedigree
1
2007
477
0.070
Why?
Radiography
1
2008
850
0.070
Why?
Doxorubicin
1
2006
313
0.070
Why?
Forecasting
1
2007
389
0.070
Why?
DNA Damage
1
2007
365
0.070
Why?
Signal Transduction
2
2016
4890
0.070
Why?
Gastrointestinal Diseases
1
2006
200
0.070
Why?
Metabolic Syndrome
1
2008
391
0.070
Why?
Diagnosis, Differential
1
2009
1419
0.070
Why?
Melanoma
1
2011
718
0.070
Why?
Epithelial Cells
1
2010
1016
0.070
Why?
Referral and Consultation
1
2009
648
0.070
Why?
Radiotherapy
2
2015
197
0.060
Why?
Carcinoma, Non-Small-Cell Lung
1
2012
986
0.060
Why?
Young Adult
4
2021
10987
0.060
Why?
Maximum Tolerated Dose
2
2013
189
0.060
Why?
Immunohistochemistry
2
2020
1783
0.060
Why?
Disease Models, Animal
1
2012
3828
0.060
Why?
Immune System Diseases
1
2002
31
0.060
Why?
Steroid Synthesis Inhibitors
1
2021
1
0.060
Why?
Follow-Up Studies
2
2015
4950
0.060
Why?
Clinical Trials, Phase III as Topic
1
2021
76
0.060
Why?
Proteomics
1
2007
768
0.050
Why?
Prednisolone
1
2021
76
0.050
Why?
Bevacizumab
1
2021
124
0.050
Why?
Tumor Burden
1
2021
288
0.050
Why?
Asymptomatic Diseases
1
2021
72
0.050
Why?
Metabolic Diseases
1
2002
116
0.050
Why?
Mass Screening
1
2008
1066
0.050
Why?
Deoxycytidine
1
2021
141
0.050
Why?
Ytterbium
1
2018
2
0.050
Why?
Erbium
1
2018
4
0.050
Why?
Estrogen Receptor alpha
1
2020
113
0.050
Why?
HLA-A2 Antigen
1
2019
38
0.050
Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
230
0.050
Why?
Neovascularization, Pathologic
1
2021
295
0.050
Why?
Fruit and Vegetable Juices
1
2018
14
0.050
Why?
Luminescent Measurements
1
2018
77
0.040
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
158
0.040
Why?
Lasers
1
2018
115
0.040
Why?
Risk Assessment
1
2008
3208
0.040
Why?
Laparoscopy
1
2021
395
0.040
Why?
National Cancer Institute (U.S.)
1
2017
38
0.040
Why?
Biomarkers
1
2007
3485
0.040
Why?
Risk Reduction Behavior
1
2018
220
0.040
Why?
Antibodies
1
2018
422
0.040
Why?
Abdominal Neoplasms
1
2015
32
0.040
Why?
Thoracic Neoplasms
1
2015
36
0.040
Why?
Molecular Diagnostic Techniques
1
2016
97
0.040
Why?
Placebos
1
2015
212
0.040
Why?
Nanoconjugates
1
2014
2
0.030
Why?
Spectrophotometry, Atomic
1
2014
14
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2015
132
0.030
Why?
Platelet Aggregation Inhibitors
1
2018
397
0.030
Why?
Administration, Oral
1
2017
796
0.030
Why?
Smoking Cessation
1
2018
389
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2015
135
0.030
Why?
Antihypertensive Agents
1
2018
458
0.030
Why?
Lipids
1
2018
622
0.030
Why?
Benchmarking
1
2015
156
0.030
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
401
0.030
Why?
Accidental Falls
1
2015
152
0.030
Why?
Cell Death
1
2014
337
0.030
Why?
Hydroxamic Acids
1
2012
88
0.030
Why?
Dose-Response Relationship, Radiation
1
2011
126
0.030
Why?
Health Policy
1
2014
361
0.030
Why?
Blood Pressure
1
2018
1726
0.030
Why?
Histone Deacetylase Inhibitors
1
2012
201
0.030
Why?
Androgens
1
2011
159
0.020
Why?
Fatigue
1
2011
301
0.020
Why?
Seizures
1
2012
329
0.020
Why?
Polyethylene Glycols
1
2014
579
0.020
Why?
Sex Factors
1
2014
1971
0.020
Why?
Multivariate Analysis
1
2012
1600
0.020
Why?
Radionuclide Imaging
1
2007
155
0.020
Why?
Positron-Emission Tomography
1
2009
303
0.020
Why?
Cell Membrane Permeability
1
2006
90
0.020
Why?
Head and Neck Neoplasms
1
2008
420
0.020
Why?
Cell Survival
1
2006
1134
0.020
Why?
Ultrasonography
1
2006
783
0.010
Why?
Incidence
1
2008
2454
0.010
Why?
Neoplasms
1
2013
2065
0.010
Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)